135 related articles for article (PubMed ID: 36326962)
1. Relative dose intensity and 1-year psoas muscle index reduction rate as prognostic factors in gastric cancer patients with postoperative adjuvant chemotherapy.
Fujita S; Sakuramoto S; Matsui K; Ebara G; Nishibeppu K; Oya S; Fujihata S; Lee S; Miyawaki Y; Sugita H; Sato H; Yamashita K
Int J Clin Oncol; 2023 Jan; 28(1):110-120. PubMed ID: 36326962
[TBL] [Abstract][Full Text] [Related]
2. Impact of loss of skeletal muscle mass within 6-12 months after gastrectomy and S1 adjuvant chemotherapy on the survival prognosis of elderly patients with gastric cancer.
Fujihata S; Sakuramoto S; Morimoto Y; Matsui K; Nishibeppu K; Ebara G; Fujita S; Oya S; Sugita H; Lee S; Miyawaki Y; Sato H; Takiguchi S; Yamashita K
Surg Today; 2022 Oct; 52(10):1472-1483. PubMed ID: 35394206
[TBL] [Abstract][Full Text] [Related]
3. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
[TBL] [Abstract][Full Text] [Related]
4. Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on long-term outcomes after gastrectomy.
Horii N; Kosaka T; Fujiwara R; Sato S; Akiyama H; Kunisaki C; Endo I
Asia Pac J Clin Oncol; 2022 Feb; 18(1):61-69. PubMed ID: 33644991
[TBL] [Abstract][Full Text] [Related]
5. Impact of neutrophil-lymphocyte ratio, Glasgow Prognostic Score, and postoperative decrease in psoas muscle index on recurrence after curative gastrectomy.
Nakazawa N; Sohda M; Ogata K; Sano A; Sakai M; Ogawa H; Kobayashi K; Iwanami K; Maemura M; Shirabe K; Saeki H
J Med Invest; 2021; 68(1.2):119-124. PubMed ID: 33994455
[TBL] [Abstract][Full Text] [Related]
6. Preoperative low skeletal muscle volume can result in insufficient administration of S-1 adjuvant chemotherapy in older patients with stage II/III gastric cancer.
Kono Y; Matsunaga T; Makinoya M; Shimizu S; Shishido Y; Miyatani K; Kihara K; Yamamoto M; Takano S; Tokuyasu N; Sakamoto T; Hasegawa T; Fujiwara Y
Surg Today; 2024 Apr; 54(4):340-346. PubMed ID: 37589768
[TBL] [Abstract][Full Text] [Related]
7. Impact of visceral adipose tissue on compliance of adjuvant chemotherapy and relapse-free survival after gastrectomy for gastric cancer: A propensity score matching analysis.
Matsui R; Inaki N; Tsuji T
Clin Nutr; 2021 May; 40(5):2745-2753. PubMed ID: 33933740
[TBL] [Abstract][Full Text] [Related]
8. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
9. Impacts of Preoperative Psoas Muscle Mass and Visceral Fat Area on Postoperative Short- and Long-Term Outcomes in Patients with Gastric Cancer.
Taniguchi Y; Kurokawa Y; Takahashi T; Saito T; Yamashita K; Tanaka K; Makino T; Yamasaki M; Nakajima K; Eguchi H; Doki Y
World J Surg; 2021 Mar; 45(3):815-821. PubMed ID: 33179125
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
12. Real-World Therapeutic Outcomes of S-1 Adjuvant Chemotherapy for pStage II/III Gastric Cancer in the Elderly.
Kunisaki C; Sato S; Tsuchiya N; Kubo H; Watanabe J; Sato T; Takeda K; Tamura Y; Kasahara K; Kosaka T; Akiyama H; Endo I
Eur Surg Res; 2021; 62(1):40-52. PubMed ID: 33794520
[TBL] [Abstract][Full Text] [Related]
13. [The value of spleen density in predicting prognosis of patients with gastric cancer after curative gastrectomy].
Li S; Ma PF; Zhang JL; Cao YH; Liu CY; Zhang XJ; Li ZY; Xue YW; Zhao YZ
Zhonghua Yi Xue Za Zhi; 2021 Sep; 101(34):2703-2709. PubMed ID: 34510877
[No Abstract] [Full Text] [Related]
14. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
15. [Impact of Muscle Mass Reduction on Postoperative Adjuvant Chemotherapy and Long-Term Prognosis in Patients with Gastric Cancer].
Nagata T; Fukuda K; Tamai M; Taniguchi A; Kamiya H; Kanbe K; Kamada Y; Iwata J; Yamaoka N; Tsukamoto K
Gan To Kagaku Ryoho; 2018 Dec; 45(13):1915-1918. PubMed ID: 30692396
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
Ogawa K; Honda M; Akashi Y; Inagawa S; Kaneda A; Hori S; Owada Y; Ohara Y; Hisakura K; Enomoto T; Shimomura O; Takahashi K; Oda T
Int J Clin Oncol; 2020 Oct; 25(10):1807-1813. PubMed ID: 32533352
[TBL] [Abstract][Full Text] [Related]
18. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer.
Nishibeppu K; Komatsu S; Ichikawa D; Imamura T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
BMC Cancer; 2018 Jan; 18(1):108. PubMed ID: 29382310
[TBL] [Abstract][Full Text] [Related]
19. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
20. Psoas muscle mass in patients undergoing lung cancer surgery: a prognostic difference between squamous cell carcinoma and adenocarcinoma.
Ozeki N; Kawaguchi K; Fukui T; Nakamura S; Hakiri S; Mori S; Goto M; Iwano S; Yokoi K; Chen-Yoshikawa TF
Int J Clin Oncol; 2020 May; 25(5):876-884. PubMed ID: 31955305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
